Elastography in the Diagnosis of Non-Alcoholic Fatty Liver Disease

Cover Page
  • Authors: Shirokova E.N.1, Pavlov C.S.1, Karaseva A.D.1, Alieva A.M.1, Sedova A.V.1, Ivashkin V.T.1
  • Affiliations:
    1. Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
  • Issue: Vol 74, No 1 (2019)
  • Pages: 5-13
  • Section: INTERNAL DISEASES: CURRENT ISSUES
  • URL: https://vestnikramn.spr-journal.ru/jour/article/view/1071
  • DOI: https://doi.org/10.15690/vramn1071
  • Cite item
Open Access Open Access
Restricted Access Subscription or Fee Access

Abstract


Currently, there has been a progressive increase in prevalence of one of the most common diffuse chronic liver diseases ― non-alcoholic fatty liver disease (NAFLD). Assessment of the stages of liver fibrosis and steatosis is prognostically significant in diagnosis of NAFLD. Routine diagnostic methods are either not able to accurately assess the severity of fibrosis and steatosis (ultrasound, laboratory tests), or cannot be used as a simple screening tool (liver biopsy) due to such limitations as invasiveness, dependence on pathologist qualification, high cost, and limited region of interest. Over the last two decades, the great progress has been made in non-invasive visualization of pathological changes in liver diseases. In this review, we examined the diagnostic characteristics of the most widely used non-invasive imaging methods in clinical practice, available for quantitative determination of fat and fibrosis in the liver: transient elastography with controlled attenuation parameter (CAP), acoustic radiation force impulse (ARFI) and shear wave elastography (SWE). Comparing these methods and their limitations, we came to conclusion, that elastographic methods (slightly more ARFI and SWE) are able to verify the F3, F4 stages of fibrosis in NAFLD with high sensitivity and specificity (>90%); however, they are less accurate for early stages. Elastographic techniques have moderate accuracy in identifying the degree of steatosis due to the lack of uniform standardized cut-off values of CAP.

Elena N. Shirokova

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: elshirokova@yandex.ru
ORCID iD: 0000-0002-6819-0889

Russian Federation

Elena Nikolaevna Shirokova - MD, PhD, Professor

SPIN-код: 7340-4526

Chavdar S. Pavlov

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: chpavlov@mail.ru
ORCID iD: 0000-0001-5031-9798

Russian Federation

Chavdar Savov Pavlov - MD, PhD, Professor

SPIN-код: 5052-9020

Anna D. Karaseva

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Author for correspondence.
Email: karas_any@list.ru
ORCID iD: 0000-0002-9200-1590

Russian Federation

Anna Dmitrievna Karaseva

1 bld.1, Pogodinskaya street, 119435 Moscow

SPIN-код: 6745-7823

Aliya M. Alieva

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: aliya1993@mail.ru
ORCID iD: 0000-0002-7606-2246

Russian Federation

Aliya Mahmudovna Alieva - MD

SPIN-код: 2680-5872

Alla V. Sedova

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: sedovaav@yandex.ru
ORCID iD: 0000-0003-1644-264X

Russian Federation

Alla Vladimirovna Sedova - MD, PhD

SPIN-код: 7863-2295

Vladimir T. Ivashkin

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: 2135833@mail.ru
ORCID iD: 0000-0002-6815-6015

Russian Federation

Vladimir Trofimovich Ivashkin - MD, PhD, Professor

SPIN-код: 3551-0890

  1. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. ― 2016. ― Т.26. ― №2 ― С. 24–42.
  2. Saucedo RS. Harmful use of alcohol, alcohol use disorders and alcoholic liver diseases [Internet]. Update on 2004 Background Paper, BP 6.14 Alcohol Use Disorders [cited 2019 Jan 9]. Available from: https://www.who.int/medicines/areas/priority_medicines/BP6_14Alcohol.pdf.
  3. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. doi: 10.1016/j.jhep.2015.11.004.
  4. Byrne C, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1):S47–S64. doi: 10.1016/j.jhep.2014.12.012.
  5. Ивашкин В.Т., Драпкина О.М., Маев И.В., и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2 // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. ― 2016. ― Т.25. ― №6 ― С. 31–41.
  6. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–1554. doi: 10.1002/hep.27368.
  7. Широкова Е.Н. Неалкогольная жировая болезнь печени, гиперлипидемия и сердечно-сосудистые риски // Гастроэнтерология. Приложение к журналу Consilium Medicum. ― 2017. ― №2 ― С. 74–76.
  8. Dulai P, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557–1565. doi: 10.1002/hep.29085.
  9. Angulo P, Kleiner D, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–397. doi: 10.1053/j.gastro.2015.04.043.
  10. Маев И.В., Андреев Д.Н., Дичева Д.Т., Кузнецова Е.И. Неалкогольная жировая болезнь печени: пособие для врачей. ― М.: Прима Принт; 2017.
  11. Laurent A, Nicco C, Tran Van Nhieu J, et al. Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis. Hepatology. 2004;39(5):1277–1285. doi: 10.1002/hep.20177.
  12. Povero D, Feldstein A. Novel molecular mechanisms in the development of non-alcoholic steatohepatitis. Diabetes Metab J. 2016;40(1):1–11. doi: 10.4093/dmj.2016.40.1.1.
  13. Ивашкин В.Т., Павлов Ч.С. Фиброз печени. ― М.: ГЭОТАР-Медиа; 2011.
  14. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994;20(1 Pt 1):15–20. doi: 10.1016/0270-9139(94)90128-7.
  15. Knodell R, Ishak K, Black W, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1(5):431–435. doi: 10.1002/hep.1840010511.
  16. Kleiner D, Brunt E, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–1321. doi: 10.1002/hep.20701.
  17. Павлов Ч.С., Глушенков Д.В., Ивашкин В.Т. Современные возможности эластометрии, фибро- и акти-теста в диагностике фиброза печени // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. ― 2008. ― Т.18. ― №4 ― С. 43–52.
  18. Морозова Т.Г., Борсуков А.В., Мамошин А.В. Комплексная эластография печени и поджелудочной железы // Медицинская визуализация. ― 2015. ― №3 ― С. 75–83.
  19. Shiina T. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 1: basic principles and terminology. Ultrasound Med Biol. 2017;43 Suppl 1:S191–S192. doi: 10.1016/j.ultrasmedbio.2017.08.1653.
  20. Mikolasevic I, Orlic L, Franjic N, et al. Transient elastography (FibroScan) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease ― where do we stand? World J Gastroenterol. 2016;22(32):7236–7251. doi: 10.3748/wjg.v22.i32.7236.
  21. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48(5):835–847. doi: 10.1016/j.jhep.2008.02.008.
  22. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237–264. doi: 10.1016/j.jhep.2015.04.006.
  23. Al-Shaalan R, Aljiffry M, Al-Busafi S, et al. Nonalcoholic fatty liver disease: noninvasive methods of diagnosing hepatic steatosis. Saudi J Gastroenterol. 2015;21(2):64–70. doi: 10.4103/1319-3767.153812.
  24. Imajo K, Honda Y, Kessoku T, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. J Hepatol. 2016;64(2):S175–S176. doi: 10.1016/s0168-8278(16)01693-7.
  25. Pathik P, Ravindra S, Ajay C, et al. Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from Western India. Ann Gastroenterol. 2015;28(5):281–286. doi: 10.1016/j.cgh.2015.04.153.
  26. Cassinotto C, Boursier J, de Lédinghen V, et al. Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology. 2016;63(6):1817–1827. doi: 10.1002/hep.28394.
  27. Wong V, Vergniol J, Wong G, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2009;51(2):454–462. doi: 10.1002/hep.23312.
  28. Kumar R, Rastogi A, Sharma M, et al. Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation. Dig Dis Sci. 2012;58(1):265–274. doi: 10.1007/s10620-012-2306-1.
  29. Carey E, Carey WD. Noninvasive tests for liver disease, fibrosis, and cirrhosis: is liver biopsy obsolete? Cleve Clin J Med. 2010;77(8):519–527. doi: 10.3949/ccjm.77a.09138.
  30. Myers R, Pomier-Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2011;55(1):199–208. doi: 10.1002/hep.24624.
  31. Kwok R, Tse YK, Wong GL, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease ― the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014;39(3):254–269. doi: 10.1111/apt.12569.
  32. Loomba R. Role of imaging-based biomarkers in NAFLD: recent advances in clinical application and future research directions. J Hepatol. 2018;68(2):296–304. doi: 10.1016/j.jhep.2017.11.028.
  33. Vuppalanchi R, Siddiqui M, Van Natta M et al. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology. 2017;67(1):134-144. doi: 10.1002/hep.29489.
  34. Suzuki K, Yoneda M, Imajo K, et al. Transient elastography for monitoring the fibrosis of non-alcoholic fatty liver disease for 4 years. Hepatol Res. 2013;43(9):979–983. doi: 10.1111/hepr.12039.
  35. Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825–1835. doi: 10.1016/j.ultrasmedbio.2010.07.005.
  36. de Lédinghen V, Vergniol J, Foucher J, et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012;32(6):911–918. doi: 10.1111/j.1478-3231.2012.02820.x.
  37. Shen F. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol. 2014;20(16):4702. doi: 10.3748/wjg.v20.i16.4702.
  38. Kumar M, Rastogi A, Singh T, et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance? J Gastroenterol Hepatol. 2013;28(7):1194–1201. doi: 10.1111/jgh.12134.
  39. Myers R, Pollett A, Kirsch R, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32(6):902–910. doi: 10.1111/j.1478-3231.2012.02781.x.
  40. Lupșor-Platon M, Feier D, Stefănescu H, et al. Diagnostic accuracy of controlled attenuation parameter measured by transient elastography for the non-invasive assessment of liver steatosis: a prospective study. J Gastrointestin Liver Dis. 2015;24(1):35–42. doi: 10.15403/jgld.2014.1121.mlp.
  41. Friedrich-Rust M, Hadji-Hosseini H, Kriener S, et al. Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis. Eur Radiol. 2010;20(10):2390–2396. doi: 10.1007/s00330-010-1820-9.
  42. Wong VW, Vergniol J, Wong GL, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2012;107(12):1862–1871. doi: 10.1038/ajg.2012.331.
  43. Palmeri M, Wang M, Rouze N, et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol. 2011;55(3):666–672. doi: 10.1016/j.jhep.2010.12.019.
  44. Liu H, Fu J, Hong R, et al. Acoustic radiation force impulse elastography for the non-invasive evaluation of hepatic fibrosis in non-alcoholic fatty liver disease patients: a systematic review & meta-analysis. PLoS One. 2015;10(7):e0127782. doi: 10.1371/journal.pone.0127782.
  45. Fierbinteanu Braticevici C, Sporea I, Panaitescu E, Tribus L. Value of acoustic radiation force impulse imaging elastography for non-invasive evaluation of patients with nonalcoholic fatty liver disease. Ultrasound Med Biol. 2013;39(11):1942–1950. doi: 10.1016/j.ultrasmedbio.2013.04.019.
  46. Ferraioli G, Tinelli C, Zicchetti M, et al. Reproducibility of real-time shear wave elastography in the evaluation of liver elasticity. Eur J Radiol. 2012;81(11):3102–3106. doi: 10.1016/j.ejrad.2012.05.030.
  47. Диомидова В.Н., Петрова О.В. Сравнительный анализ результатов эластографии сдвиговой волной и транзиентной эластографии в диагностике диффузных заболеваний печени // Ультразвуковая и функциональная диагностика. ― 2013. ― №5 ― С. 17–23.
  48. Friedrich-Rust M, Nierhoff J, Lupsor M, et al. Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat. 2011;19(2):e212–e219. doi: 10.1111/j.1365-2893.2011.01537.x.

Views

Abstract - 215

PDF (Russian) - 2

Cited-By


PlumX

Dimensions



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies